EA201290975A1 - Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии - Google Patents

Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии

Info

Publication number
EA201290975A1
EA201290975A1 EA201290975A EA201290975A EA201290975A1 EA 201290975 A1 EA201290975 A1 EA 201290975A1 EA 201290975 A EA201290975 A EA 201290975A EA 201290975 A EA201290975 A EA 201290975A EA 201290975 A1 EA201290975 A1 EA 201290975A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phytocannabinoid
cbdv
epilepsy
treatment
cannabidivarin
Prior art date
Application number
EA201290975A
Other languages
English (en)
Other versions
EA201290975A8 (ru
EA036044B1 (ru
Inventor
Бенджамин Уэлли
Клэр Уилльямс
Гэри Стефенс
Такаси Футамура
Original Assignee
ДжиДаблЮ ФАРМА ЛИМИТЕД
Оцука Фармасьютикал Ко., Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1005364.3A external-priority patent/GB2479153B/en
Priority claimed from GB1100042.9A external-priority patent/GB2487183B/en
Application filed by ДжиДаблЮ ФАРМА ЛИМИТЕД, Оцука Фармасьютикал Ко., Лимитед filed Critical ДжиДаблЮ ФАРМА ЛИМИТЕД
Publication of EA201290975A1 publication Critical patent/EA201290975A1/ru
Publication of EA201290975A8 publication Critical patent/EA201290975A8/ru
Publication of EA036044B1 publication Critical patent/EA036044B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Изобретение относится к применению фитоканнабиноида каннабидиварина (CBDV) и комбинаций фитоканнабиноида CBDV с тетрагидроканнабиварином (THCV) и каннабидиолом (CBD) для лечения эпилепсии. Изобретение также относится к применению фитоканнабиноида CBDV в комбинации со стандартными антиэпилептическими лекарственными средствами (SAED). Предпочтительно SAED представляет собой один из этозуксимида, вальпроата или фенобарбитала.
EA201290975A 2010-03-30 2011-03-30 Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии EA036044B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1005364.3A GB2479153B (en) 2010-03-30 2010-03-30 The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB1100042.9A GB2487183B (en) 2011-01-04 2011-01-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
PCT/GB2011/050649 WO2011121351A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy

Publications (3)

Publication Number Publication Date
EA201290975A1 true EA201290975A1 (ru) 2013-04-30
EA201290975A8 EA201290975A8 (ru) 2017-02-28
EA036044B1 EA036044B1 (ru) 2020-09-17

Family

ID=43983229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290975A EA036044B1 (ru) 2010-03-30 2011-03-30 Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии

Country Status (18)

Country Link
US (3) US9125859B2 (ru)
EP (2) EP3763361B1 (ru)
JP (1) JP5918748B2 (ru)
KR (1) KR101849703B1 (ru)
CN (1) CN103025325B (ru)
AR (1) AR080730A1 (ru)
AU (3) AU2011234225B2 (ru)
BR (1) BR112012024480A8 (ru)
CA (1) CA2794620C (ru)
EA (1) EA036044B1 (ru)
IL (1) IL222132B (ru)
MX (1) MX2012011033A (ru)
MY (1) MY162129A (ru)
NZ (1) NZ602925A (ru)
SG (2) SG184236A1 (ru)
TW (1) TWI583374B (ru)
WO (1) WO2011121351A1 (ru)
ZA (1) ZA201208141B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1811983B1 (en) * 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2487183B (en) * 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
ES2739292T3 (es) * 2013-10-29 2020-01-30 Biotech Inst Llc Cultivo, producción, procesamiento y uso de cannabis de especialidad
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
EP3193862B1 (en) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Topical cannabinoid composition for treating arthritic pain
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
MX2017009846A (es) 2015-01-31 2018-04-11 Constance Therapeutics Inc Metodos para la preparacion de extractos y composiciones de aceite de cannabis.
CA2977802A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3288592A4 (en) * 2015-04-28 2019-01-09 The Regents of The University of California USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
EP3380096A4 (en) 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10053407B2 (en) 2016-06-01 2018-08-21 S&B Pharma, Inc. Crystalline cannabidivarin
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
JP2019524655A (ja) 2016-06-29 2019-09-05 キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． 脱炭酸大麻樹脂、その使用、及びそれを製造する方法
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
KR20210013645A (ko) 2016-08-03 2021-02-04 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
WO2018044953A1 (en) 2016-08-29 2018-03-08 Ebbu, LLC Water soluble compositions comprising purified cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CN110582206A (zh) * 2017-03-01 2019-12-17 凯诺比生长公司 包含纯化的大麻素和/或纯化的萜烯的有目的地选择的组合物
CN109106699A (zh) * 2017-06-23 2019-01-01 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
CN109498606A (zh) 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
AU2018379109A1 (en) * 2017-12-08 2020-07-02 Biotech Institute LLC Propyl cannabinoid hemp plants, methods of producing and methods of using them
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US20220015397A1 (en) * 2018-12-10 2022-01-20 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
US20220183998A1 (en) * 2019-03-08 2022-06-16 The Regents Of The University Of California Use of 8,9- dihydrocannabidiol compounds
GB201916977D0 (en) * 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
EP4069215A4 (en) 2019-12-06 2024-01-17 Jlabs Beauty LLC TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF PREPARING AND USING THE SAME
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
KR102371269B1 (ko) 2020-03-11 2022-03-07 연세대학교 산학협력단 VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법
CA3177186A1 (en) * 2020-03-31 2021-10-07 Phytotherapeutix Ltd Terpenophenolic compounds and their use
AU2021276680A1 (en) 2020-05-22 2023-01-19 Ilera Derm LLC Compositions for treating acne and dermatological conditions
WO2022026613A2 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US20240000808A1 (en) * 2020-11-16 2024-01-04 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022122904A1 (en) 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
GB2606334A (en) 2021-02-12 2022-11-09 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
GB0103638D0 (en) * 2001-02-14 2001-03-28 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) * 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
MXPA05001567A (es) * 2002-08-14 2005-04-25 Gw Pharma Ltd Formulaciones liquidas de canabinoides para la administracion a traves de la mucosa.
CN1691954B (zh) 2002-08-14 2010-12-08 Gw药品有限公司 对得自植物材料的药学活性大麻类物质的提取
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
EP1811983B1 (en) * 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2008094181A2 (en) 2007-02-01 2008-08-07 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
PT2280687T (pt) 2008-03-26 2019-06-04 Stichting Sanammad Composições de goma de mascar compreendendo canabinóides
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
RU2639120C2 (ru) 2011-08-26 2017-12-19 Биал-Портела Энд Ка, С.А. Лечение с использованием ацетата эсликарбазепина или эсликарбазепина
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
IL249197B2 (en) 2014-05-29 2024-09-01 Insys Pharma Inc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
EP3763361A1 (en) 2021-01-13
US20150320698A1 (en) 2015-11-12
ZA201208141B (en) 2013-06-26
MY162129A (en) 2017-05-31
US9125859B2 (en) 2015-09-08
US20210100755A1 (en) 2021-04-08
SG184236A1 (en) 2012-10-30
KR101849703B1 (ko) 2018-04-17
AR080730A1 (es) 2012-05-02
AU2011234225A1 (en) 2012-11-08
NZ602925A (en) 2014-11-28
CN103025325A (zh) 2013-04-03
EP3763361B1 (en) 2024-06-26
AU2011234225B2 (en) 2016-11-03
AU2018217303A1 (en) 2018-09-06
SG10201502480XA (en) 2015-05-28
EA201290975A8 (ru) 2017-02-28
BR112012024480A2 (pt) 2016-05-31
MX2012011033A (es) 2013-02-26
KR20130065646A (ko) 2013-06-19
WO2011121351A1 (en) 2011-10-06
US12023305B2 (en) 2024-07-02
BR112012024480A8 (pt) 2018-04-03
IL222132B (en) 2018-04-30
CA2794620A1 (en) 2011-10-06
JP2013523708A (ja) 2013-06-17
US20120004251A1 (en) 2012-01-05
EA036044B1 (ru) 2020-09-17
US10799467B2 (en) 2020-10-13
EP2552430A1 (en) 2013-02-06
AU2016244223A1 (en) 2016-11-03
TWI583374B (zh) 2017-05-21
JP5918748B2 (ja) 2016-05-18
TW201138759A (en) 2011-11-16
CA2794620C (en) 2018-03-13
CN103025325B (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
EA201290975A1 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
BR112016029506A2 (pt) canabidiol, e, método para tratamento de epilepsia resistente a tratamento.
ES2877502T8 (es) Uso del fitocannabinoide cannabidiol (CBD) en combinación con un fármaco antiepiléptico estándar (SAED) en el tratamiento de la epilepsia
GT201500081A (es) Derivados de exendina-4 como agonistas duales de glp1/glucagón
GB2479153B (en) The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
BR112015013105A2 (pt) composições de irna de pcsk9 e métodos de uso das mesmas
EA201591166A1 (ru) Ингибиторы аутотаксина
MY156444A (en) Anti-tumoural effects of cannabinoid combinations
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
BR112013022234A2 (pt) emulsão de dodecafluorpentano como uma terapia de acidente vascular cerebral e isquemia
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX2017004761A (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico.
MX370055B (es) Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
GB2487183B (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
TR201902517T4 (tr) 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112014030406A8 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação